XIAP and prostate carcinoma: Percentages of patients showing positive immunohistochemical reactions to c-IAP-2, c-IAP-1/2 and ILP in normal prostate (NP), benign prostatic hyperplasia (BPH), prostatic carcinoma (PC) and average optical densities of immunostaining in positive patients.